A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted.
Also Known As:
A-Thalassemia; A-Thalassemias; Disease, Hemoglobin H; Diseases, Hemoglobin H; Hemoglobin H Diseases; Thalassemia alpha; Thalassemia-alphas; alpha Thalassemia; alpha-Thalassemias; Hemoglobin H Disease; Thalassemia-alpha
Networked: 964 relevant articles (7 outcomes, 102 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Anemia
2. Hydrops Fetalis (Fetal Edema)
3. Sickle Cell Anemia (Hemoglobin S Disease)
4. Bronchitis
5. Congenital Abnormalities (Deformity)


1. Fucharoen, Supan: 21 articles (01/2015 - 01/2002)
2. Fucharoen, Goonnapa: 19 articles (01/2015 - 01/2002)
3. Harteveld, Cornelis L: 18 articles (10/2011 - 08/2002)
4. Sanchaisuriya, Kanokwan: 17 articles (01/2015 - 01/2002)
5. Giordano, Piero C: 17 articles (08/2010 - 08/2002)
6. Fucharoen, Suthat: 14 articles (02/2012 - 05/2002)
7. Higgs, Douglas R: 10 articles (11/2008 - 02/2002)
8. Fucharoen, S: 10 articles (10/2003 - 01/2000)
9. Winichagoon, Pranee: 9 articles (05/2010 - 05/2002)
10. van Delft, Peter: 9 articles (01/2010 - 08/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to alpha-Thalassemia:
1. DNA (Deoxyribonucleic Acid)IBA
2. hemoglobin Bart'sIBA
3. IronIBA
4. Fetal Hemoglobin (Hemoglobin F)IBA
5. Hemoglobin EIBA
6. OxygenIBA
7. zeta-GlobinsIBA
8. Hydroxyurea (Hydrea)FDA LinkGeneric
9. PolymersIBA
01/01/1989 - "Our analyses of equilibrium polymer formation at physiological oxygen saturation values suggest that small decreases in polymer formation at intermediate levels of hemoglobin F may give rise to a small decrease in anemia (as associated with homozygous alpha-thalassemia coexistent with sickle cell anemia), but that greater reductions in polymer formation may be necessary to effect a significant improvement in disease severity. "
01/01/1985 - "In our studies, the polymer fraction in sickle red cells was determined from reported mean values for hemoglobin composition and mean corpuscular hemoglobin concentration (MCHC) in 12 groups of patients with sickle hemoglobinopathies (homozygotes for HbS, with and without coexistent alpha-thalassemia or various forms of the hereditary persistence of fetal hemoglobin [HPFH], beta+-, beta 0-, and delta beta-thalassemia, and heterozygotes for HbS with HbA). "
02/13/2009 - "To achieve the best CE separation, several parameters were evaluated for optimizing the separation conditions, including the capillary coating, the concentrations of polymer sieving matrix, the sizes and concentrations of GNPs, the buffer concentrations, and the pH. The final CE method for separating a 200-base pair (bp) DNA ladder and alpha-thalassemia deletions used a DB-17 capillary, 0.6% poly(ethylene oxide) (PEO) prepared in a mixture of GNP(32nm) solution and glycine buffer (25mM, pH 9.0) (80:20, v/v) as the sieving matrix with 1microM YO-PRO-1 for fluorescence detection; the applied voltage was -10kV (detector at anode side) and the separation temperature was 25 degrees C. "
10. CalciumIBA

Therapies and Procedures

1. Prenatal Care
2. Ligation
3. Splenectomy
4. Continuous Ambulatory Peritoneal Dialysis (CAPD)
5. Renal Dialysis (Hemodialysis)